Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma

Blood (2020) 136 (Supplement 1): 46–47.

https://doi.org/10.1182/blood-2020-136219

Published: 2020

Journal Articles

Dose-Dense Brentuximab Vedotin Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Is Highly Active for Second Line Treatment in Relapsed/Refractory Classical Hodgkin Lymphoma: Final Results of a Phase I/II Study

Blood (2020) 136 (Supplement 1): 16–18.

https://doi.org/10.1182/blood-2020-133763

Published: 2020

Journal Articles

Ixazomib-Rituximab in Untreated Indolent B-NHL: An Effective, Very Low Toxicity Regimen

Solomon A. Graf, MD, Ryan C. Lynch, MD, Ted A Gooley, PhD, Chaitra S. Ujjani, MD, Peter Wilcox, Sabrina Wilcox, David G. Coffey, MD, Andrew J. Cowan, MD, Stephen D. Smith, MD, Mazyar Shadman, MDMPH, Edus H. Warren, MD PhD, Edward Libby, MD, Colin D. Godwin, MDMPhil, Ryan D. Cassaday, MD, Jonathan R. Fromm, MD PhD, Ajay K. Gopal, MD

Blood (2020) 136 (Supplement 1): 4.

https://doi.org/10.1182/blood-2020-137226

Published: 2020

Journal Articles

Third Generation CD20 Targeted CAR T-Cell Therapy (MB-106) for Treatment of Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Blood (2020) 136 (Supplement 1): 38–39.

https://doi.org/10.1182/blood-2020-136440

Published: 2020

Journal Articles

Low Achievement of End of Life Quality Measures in Large B-Cell Lymphoma Patients Who Progressed after CD19-Specific CAR-T Cell Therapy

Ryan C. Lynch, MD, Victor A. Chow, MD, David G. Maloney, MD PhD, Cameron J. Turtle, MBBS, PhD, Mazyar Shadman, MD, Chaitra S. Ujjani, MD, Ryan D. Cassaday, MD, Brian G. Till, MD, Yolanda D. Tseng, MD, Edus H. Warren, MD PhD, Andrei R Shustov, MD, Manoj P. Menon, MD, Elizabeth Loggers, MD PhD, Jenna M. Voutsinas, MPH, Ted Gooley, PhD, Ajay K. Gopal, MD, Stephen D. Smith, MD

Blood (2019) 134 (Supplement_1): 413.

https://doi.org/10.1182/blood-2019-124857

Published: 2019

Journal Articles

High-Throughput Functional Drug Screening and Genomic Analysis to Guide Individualized Therapy for Relapsed/Refractory Multiple Myeloma

David G. Coffey, MD, Andrew J. Cowan, MD, Timothy S Martins, PhD, Damian J. Green, MD, Edward N. Libby, III, MD, Rebecca W. Silbermann, MD, Sylvia Chien, Jin Dai, PhD, Alicia Morales, Niall Curley, Bret Gary Degraaff, BS, Ted A Gooley, PhD, Edus H. Warren, MD PhD, Pamela S. Becker, MD PhD

Blood (2019) 134 (Supplement_1): 1885.

https://doi.org/10.1182/blood-2019-125383

Published: 2019

Journal Articles

Impact of Lab Abnormalities at the Time of Progression in Patients Receiving CD19-Specific CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphomas

Ryan C. Lynch, MD, Victor A. Chow, MD, David G. Maloney, MD PhD, Cameron J. Turtle, MBBS, PhD, Stephen D. Smith, MD, Mazyar Shadman, MD, Chaitra S. Ujjani, MD, Ryan D. Cassaday, MD, Brian G. Till, MD, Yolanda D. Tseng, MD, Edus H. Warren, MD PhD, Andrei R Shustov, MD, Manoj P. Menon, MD, Jenna M. Voutsinas, MPH, Ted Gooley, PhD, Ajay K. Gopal, MD

Blood (2019) 134 (Supplement_1): 2889.

https://doi.org/10.1182/blood-2019-124962

Published: 2019

Journal Articles

High Rate of Exclusion of HIV Infected Patients from Modern Lymphoma Studies: An Analysis of Current United States Therapeutic Trials

Manoj P. Menon, MD, Victor A. Chow, MD, Adam Greenbaum, MD PhD, Ryan C. Lynch, MD, Mazyar Shadman, MD MPH, Andrei Shustov, MD, Stephen D. Smith, MD, Brian G. Till, MD, Yolanda D. Tseng, MD, Chaitra S. Ujjani, MD, Thomas S. Uldrick, MD MS, Edus H. Warren, MD PhD, Ajay K. Gopal, MD

Blood (2019) 134 (Supplement_1): 4733.

https://doi.org/10.1182/blood-2019-127505

Published: 2019

Journal Articles

Reduced Antigen Presentation May Contribute to Immunomodulatory Drug Resistance in Multiple Myeloma

David G. Coffey, MD, Ola Landgren, MD PhD, Yuexin Xu, PhD, Dickran Kazandjian, MD, Trevor J. Pugh, PhD, Sacha Gnjatic, PhD, Edus H. Warren, MD PhD, Damian J. Green, MD

Blood (2019) 134 (Supplement_1): 4367.

https://doi.org/10.1182/blood-2019-126222

Published: 2019

Journal Articles

A Pilot Trial of Adriamycin, Pembrolizumab, Vinblastine and Dacarbazine (APVD) for Patients with Untreated Classical Hodgkin Lymphoma

Ryan C. Lynch, MD, Chaitra S. Ujjani, MD, Edus H. Warren, MD PhD, David M. Kurtz, MD PhD, Hilary Coye, PA-C, Jacquelin Vandermeer, BS, Hongyan Du, MD, Adam Greenbaum, MD PhD, Ajay K. Gopal, MD

Blood (2019) 134 (Supplement_1): 5299.

https://doi.org/10.1182/blood-2019-124997

Published: 2019

Journal Articles

Phase II Window Study of Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases

Ajay K. Gopal, MD, Adam Greenbaum, MD PhD, Ryan C. Lynch, MD, Edus H. Warren, MD PhD, Chaitra S. Ujjani, MD, Mazyar Shadman, MD, Stephen D. Smith, MD, Brian G. Till, MD, Jonathan R. Fromm, MD PhD, Andrei R Shustov, MD, Qian Vicky Wu, PhD, Manoj P. Menon, MD

Blood (2019) 134 (Supplement_1): 5258.

https://doi.org/10.1182/blood-2019-124984

Published: 2019

Journal Articles

A Window Study of Ixazomib in Untreated B-NHL

Solomon A. Graf, MD, Ryan C. Lynch, MD, Chaitra S. Ujjani, MD, David G. Coffey, MD, Andrew J. Cowan, MD, Stephen D. Smith, MD, Mazyar Shadman, MD, Edus H. Warren, MD PhD, Edward N. Libby, III, MD, Colin D. Godwin, MDMPhil, Ryan D. Cassaday, MD, Ted A Gooley, PhD, Jonathan R. Fromm, MD PhD, Ajay K. Gopal, MD

Blood (2019) 134 (Supplement_1): 5260.

https://doi.org/10.1182/blood-2019-126153

Published: 2019

Journal Articles

CD20 Targeted CAR-T for High-Risk B-Cell Non-Hodgkin Lymphomas

Mazyar Shadman, MD, Ajay K. Gopal, MD, Stephen D. Smith, MD, Ryan C. Lynch, MD, Chaitra S. Ujjani, MD, Cameron J. Turtle, MBBS, PhD, Adam Greenbaum, MD PhD, Mary Redman, Cecilia Yeung, MD, Martina Sersch, MD PhD, Edus H. Warren, MD PhD, David G. Maloney, MD PhD, Brian G. Till, MD

Blood (2019) 134 (Supplement_1): 3235.

https://doi.org/10.1182/blood-2019-125102

Published: 2019

Journal Articles

Ixazomib in Previously Untreated Indolent B-Cell Non-Hodgkin Lymphoma

Solomon A. Graf, MD, Ryan C. Lynch, MD, David G. Coffey, MD, Mazyar Shadman, MD MPH, Sandra Kanan, MSN, ARNP, Edward N. Libby, III, MD, Edus H. Warren, MD PhD, Colin Godwin, Ted Gooley, PhD, Jonathan R. Fromm, MD PhD, Ajay K. Gopal, MD

Blood (2018) 132 (Supplement 1): 5326.

https://doi.org/10.1182/blood-2018-99-117572

Published: 2018

Journal Articles

Outcomes of Patients with Large B-Cell Lymphomas and Progressive Disease Following CD19-Specific CAR T-Cell Therapy

Victor A. Chow, MD, Ajay K. Gopal, MD, David G. Maloney, MD PhD, Cameron J. Turtle, MBBS, PhD, Stephen D. Smith, MD, Mazyar Shadman, MD MPH, Ryan D. Cassaday, MD, Brian G. Till, MD, Yolanda D. Tseng, MD, Edus H. Warren, MD PhD, Andrei R. Shustov, MD, Manoj P. Menon, MD, Sandra Kanan, MSN, ARNP, Utkarsh H. Acharya, DO, Erin Mullane, DNP, Lindsay M. Hannan, MD MS, Jenna M. Voutsinas, MSc, Ted Gooley, PhD, Ryan C. Lynch, MD

Blood (2018) 132 (Supplement 1): 94.

https://doi.org/10.1182/blood-2018-99-110747

Published: 2018

Journal Articles

Eligibility for Car-T Trials: An Analysis of Selection Criteria and Survival Outcomes in Chemorefractory DLBCL

Prathima Reddy, MD, Alexandra Sokolova, MD, Victor A. Chow, MD, Ryan C. Lynch, MD, Mazyar Shadman, MD MPH, Brian G. Till, MD, Andrei R Shustov, MD, Edus H. Warren, MD PhD, Manoj P. Menon, MD, Sandra Kanan, MSN, ARNP, Yolanda D. Tseng, MD, Ajay K. Gopal, MD, Stephen D. Smith, MD

Blood (2018) 132 (Supplement 1): 2911.

https://doi.org/10.1182/blood-2018-99-119794

Published: 2018

Journal Articles

Evaluation of Published Single-Nucleotide Polymorphisms (SNPs) Associated with Cytomegalovirus Infection and Disease after Hematopoietic Cell Transplantation in a Large Caucasian Cohort

Sachiko Seo, MD, Wenhong Fan, John A. Hansen, MD, Barry E. Storer, PhD, Steven A. Pergam, MDMPH, Margaret L. Green, MD, Sezen Ozkok, MD, Sonia Goyal, MD, Cynthia Fisher, MD, Sangeeta Hingorani, MD MPH, Edus H. Warren, MD PhD, Paul J. Martin, MD, Lue Ping Zhao, Michael Boeckh, MD

Blood (2014) 124 (21): 182.

https://doi.org/10.1182/blood.V124.21.182.182

Published: 2014

Journal Articles

TCR Repertoire Diversity Assessed with Immunosequencing Is Associated with Patient Mortality Following Cord Blood Transplant

Ryan O Emerson, PhD, Sarah Nikiforow, MD PhD, Filippo Milano, MD PhD, Anna M Sherwood, PhD, Adrienne Papermaster, Katherine A. Guthrie, PhD, Christopher S Carlson, PhD, Edus H. Warren, MD PhD, Jerome Ritz, MD, Harlan Robins, PhD, Corey S Cutler, MD MPH, Colleen Delaney, MD

Blood (2014) 124 (21): 1262.

https://doi.org/10.1182/blood.V124.21.1262.1262

Published: 2014

Journal Articles

An Alternative Transcript of the PANE1 Gene Encodes a Minor Histocompatibility Antigen That Is Selectively Expressed in Resting CD19 + Cells and B-CLL.

Anthony G. Brickner, PhD, Jeffrey K. Mito, Xin Feng, MD, Tetsuya Nishida, PhD, Liane Fairfull, Robert E. Ferrell, PhD, Kenneth A. Foon, MD, Stanley R. Riddell, MD, Edus H. Warren, MD, PhD

Blood (2005) 106 (11): 2957.

https://doi.org/10.1182/blood.V106.11.2957.2957

Published: 2005

Journal Articles

A Polymorphic Oncofetal Antigen Recognized by CD8 + CTL from Two Patients Experiencing Regression of Metastatic Renal Cell Carcinoma after Allogeneic HCT.

Edus H. Warren, MD, PhD, Jeffrey K. Mito, Scott S. Tykodi, MD, PhD, John A. Thompson, MD, Brenda M. Sandmaier, MD, Rainer Storb, MD, Stanley R. Riddell, MD, Benoît Van den Eynde, MD

Blood (2005) 106 (11): 3097.

https://doi.org/10.1182/blood.V106.11.3097.3097

Published: 2005

NARROW

Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma

Dose-Dense Brentuximab Vedotin Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Is Highly Active for Second Line Treatment in Relapsed/Refractory Classical Hodgkin Lymphoma: Final Results of a Phase I/II Study

Ixazomib-Rituximab in Untreated Indolent B-NHL: An Effective, Very Low Toxicity Regimen

Third Generation CD20 Targeted CAR T-Cell Therapy (MB-106) for Treatment of Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Low Achievement of End of Life Quality Measures in Large B-Cell Lymphoma Patients Who Progressed after CD19-Specific CAR-T Cell Therapy

High-Throughput Functional Drug Screening and Genomic Analysis to Guide Individualized Therapy for Relapsed/Refractory Multiple Myeloma

Impact of Lab Abnormalities at the Time of Progression in Patients Receiving CD19-Specific CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphomas

High Rate of Exclusion of HIV Infected Patients from Modern Lymphoma Studies: An Analysis of Current United States Therapeutic Trials

Reduced Antigen Presentation May Contribute to Immunomodulatory Drug Resistance in Multiple Myeloma

A Pilot Trial of Adriamycin, Pembrolizumab, Vinblastine and Dacarbazine (APVD) for Patients with Untreated Classical Hodgkin Lymphoma

Phase II Window Study of Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases

A Window Study of Ixazomib in Untreated B-NHL

CD20 Targeted CAR-T for High-Risk B-Cell Non-Hodgkin Lymphomas

Ixazomib in Previously Untreated Indolent B-Cell Non-Hodgkin Lymphoma

Outcomes of Patients with Large B-Cell Lymphomas and Progressive Disease Following CD19-Specific CAR T-Cell Therapy

Eligibility for Car-T Trials: An Analysis of Selection Criteria and Survival Outcomes in Chemorefractory DLBCL

Evaluation of Published Single-Nucleotide Polymorphisms (SNPs) Associated with Cytomegalovirus Infection and Disease after Hematopoietic Cell Transplantation in a Large Caucasian Cohort

TCR Repertoire Diversity Assessed with Immunosequencing Is Associated with Patient Mortality Following Cord Blood Transplant

An Alternative Transcript of the PANE1 Gene Encodes a Minor Histocompatibility Antigen That Is Selectively Expressed in Resting CD19 + Cells and B-CLL.

A Polymorphic Oncofetal Antigen Recognized by CD8 + CTL from Two Patients Experiencing Regression of Metastatic Renal Cell Carcinoma after Allogeneic HCT.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only